Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial

Study Design

Subject Type

Human

Trial Design

Single-Blind, Randomised, Controlled

Trial Duration

56 days

Participants

Age Range

32-50 years

Mechanisms

Intervention(s)			Outcome		Method		Effect	Description
Rucinol			Melanin		Mexameter		🠫	Sign in to read for free
Sign in to read for free

Side Effects

Study Summary